BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline (GSK). BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). The second license agreement provides GSK with access to BioWa's COMPLEGENT® Technology for enhancing the complement-dependent cytotoxicity (CDC) of select GSK therapeutic antibodies. These two technologies may be used in a complementary or independent approach.
"We are very pleased about our expanded partnership with GSK, one of the world's leading research-based pharmaceutical and healthcare companies," commented Dr. Masamichi Koike, BioWa's President and CEO. "We are confident that these technologies will contribute materially to GSK's efforts in monoclonal antibody based therapeutics."
Under the terms of the license agreements, BioWa grants GSK non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT® and COMPLEGENT® Technologies for an undisclosed number of targets. In return, BioWa will receive upfront and annual fees, development milestone payments and royalties on products. Other details of the agreement are not disclosed.